Navigation Links
AMP cautions consumers about direct access genetic testing
Date:5/14/2010

WASHINGTON, DC (May 14, 2010) In response to recent announcements about consumer genetic tests being made available in retail drugstores, the Association for Molecular Pathology (AMP) today reiterated its position that these tests should be provided to the public only through the services of appropriate health care professionals that order tests from laboratories that are certified by CLIA for highcomplexity testing.

"Genetic testing continues to be an integral part of health care and there is great potential for future test development and use as long as they are administered properly and interpreted in the context of the overall medical evaluation of each patient," said AMP President, Karen Mann, M.D., Ph.D. "AMP is concerned that these types of direct access genetic tests will mislead consumers by making predictions that are medically unproven or not meaningful and promoting purchase of products not proven to be medically useful."


'/>"/>

Contact: Mary Steele Williams
mwilliams@amp.org
301-634-7921
Association for Molecular Pathology
Source:Eurekalert

Page: 1

Related biology news :

1. Research cautions to catch-and-release in less than 4 minutes
2. Californias wildflowers are disappearing, new book by UCR ecologist cautions
3. AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands
4. New test could help consumers avoid surprise headaches from chocolate, wine
5. Got calcium? UWM researcher finds that food labels confuse consumers
6. Alternative food networks connect ethical producers and consumers and can lead to healthier eating
7. Shell Provides Consumers Gasoline Industrys First Pay By Touch Technology at the Pump
8. Department of Energy putting power in the hands of consumers through technology
9. Consumers influence christmas tree styles
10. Cheskin Added Value EVP Lee Shupp Discusses Evolving Dynamics of Consumers and Imaging Tech at 6Sight
11. Consumers desire more genetic testing, but not designer babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Oregon (PRWEB) , ... December 08, 2016 , ... ... and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI ... not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... bioprocess media products engineered to radically streamline culture processes, minimize processing time, ...
(Date:12/8/2016)... 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a ... plans to commercialize innovative therapeutics for patients with ... were approved for trading on the OTCQX U.S. ... OTCQX, effective today, under the ticker symbol "HPPI." ... companies must meet high financial standards, follow best ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented today ... clinical trial for its lead drug candidate, AC0010, at the World Conference on ... to determine the safety, antitumor activity, and recommended phase II dosage of AC0010 ...
Breaking Biology Technology: